SG11201806894PA - Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy - Google Patents

Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy

Info

Publication number
SG11201806894PA
SG11201806894PA SG11201806894PA SG11201806894PA SG11201806894PA SG 11201806894P A SG11201806894P A SG 11201806894PA SG 11201806894P A SG11201806894P A SG 11201806894PA SG 11201806894P A SG11201806894P A SG 11201806894PA SG 11201806894P A SG11201806894P A SG 11201806894PA
Authority
SG
Singapore
Prior art keywords
international
treatment
pct
lipid lowering
lowering therapy
Prior art date
Application number
SG11201806894PA
Inventor
Charles Bisgaier
Original Assignee
Gemphire Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemphire Therapeutics Inc filed Critical Gemphire Therapeutics Inc
Publication of SG11201806894PA publication Critical patent/SG11201806894PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

WO 17 / 1475 98 Al FIG. 2 Patient 1 (40 mg osuva) Patent 2 (80 mg atorva, 10 mg ezetimibe) -18.3% -22.9% % Chang e LDL- C From Base line -28.7% -32.4% OGEM 300 mg/day (4wks) n GEM 600 mg/day (4 wks) (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/147598 Al 31 August 2017 (31.08.2017) WIPO I PCT 1111111111111101110111111111110101111101110101111111111111111111110111111111110111111 (51) International Patent Classification: A61K 31/194 (2006.01) A61P 3/06 (2006.01) A61K 45/06 (2006.01) CO7C 5 9 / 3 05 (2006.01) (21) International Application Number: PCT/US2017/019750 (22) International Filing Date: 27 February 2017 (27.02.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/300,393 26 February 2016 (26.02.2016) (71) Applicant: GEMPHIRE THERAPEUTICS INC. [US/US]; 17199 N. Laurel Park Drive, Suite 401, Livonia, MI 48152 (US). (72) Inventor: BISGAIER, Charles, L.; 3605 Tanglewood Dr, Ann Arbor, MI 48105 (US). (74) Agent: BOTT, Cynthia, M.; 350 East Michigan Avenue, Suite 300, Kalamazoo, MI 49007-3800 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). US ( 84 ) [Continued on next page] (54) Title: TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA ON LIPID LOWERING THERAPY (57) : Methods for the treatment of Homozygous Familial Hypercholester- olemia by administering gemcabene as an adjunct to other lipid lowering therapy and/or modified diet. WO 2017/147598 Al MIDEDIM000101011101010M0101111111111111111111101110110111111 Published: — with international search report (Art. 21(3))
SG11201806894PA 2016-02-26 2017-02-27 Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy SG11201806894PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662300393P 2016-02-26 2016-02-26
PCT/US2017/019750 WO2017147598A1 (en) 2016-02-26 2017-02-27 Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy

Publications (1)

Publication Number Publication Date
SG11201806894PA true SG11201806894PA (en) 2018-09-27

Family

ID=59685647

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201912756XA SG10201912756XA (en) 2016-02-26 2017-02-27 Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy
SG11201806894PA SG11201806894PA (en) 2016-02-26 2017-02-27 Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201912756XA SG10201912756XA (en) 2016-02-26 2017-02-27 Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy

Country Status (14)

Country Link
EP (1) EP3419614A4 (en)
JP (1) JP2019506423A (en)
KR (1) KR20180115722A (en)
CN (1) CN108697677A (en)
AU (1) AU2017224230A1 (en)
BR (1) BR112018067967A2 (en)
CA (1) CA3014919A1 (en)
HK (1) HK1257556A1 (en)
IL (1) IL261117A (en)
MX (1) MX2018010096A (en)
PH (1) PH12018501790A1 (en)
RU (1) RU2018133690A (en)
SG (2) SG10201912756XA (en)
WO (1) WO2017147598A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200253877A1 (en) * 2018-10-18 2020-08-13 Neurobo Pharmaceuticals, Inc. Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
AU2019389048A1 (en) * 2018-11-30 2021-06-17 Hdl Therapeutics, Inc Methods for treating lipid-related diseases including xanthomas, carotid artery stenoses, and cerebral atherosclerosis
CN112138008B (en) * 2020-09-30 2022-06-17 郑州大学 Application of lomitapide in preparation of antitumor drugs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105154A1 (en) * 2001-10-24 2003-06-05 Bisgaier Charles Larry Statin-carboxyalkylether combinations
CA2679608A1 (en) * 2006-03-22 2007-10-04 President And Fellows Of Harvard College Methods and compositions for treating hypercholesterolemia and atherosclerosis
CA2861643C (en) * 2012-01-06 2020-10-06 Charles L. Bisgaier Methods of reducing risk of cardiovascular disease

Also Published As

Publication number Publication date
KR20180115722A (en) 2018-10-23
RU2018133690A3 (en) 2020-05-29
AU2017224230A1 (en) 2018-08-30
CA3014919A1 (en) 2017-08-31
IL261117A (en) 2018-10-31
EP3419614A4 (en) 2019-10-09
WO2017147598A1 (en) 2017-08-31
JP2019506423A (en) 2019-03-07
PH12018501790A1 (en) 2019-06-17
CN108697677A (en) 2018-10-23
RU2018133690A (en) 2020-03-26
SG10201912756XA (en) 2020-02-27
HK1257556A1 (en) 2019-10-25
BR112018067967A2 (en) 2019-01-15
EP3419614A1 (en) 2019-01-02
MX2018010096A (en) 2018-11-09

Similar Documents

Publication Publication Date Title
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201906885TA (en) Methods for the administration of certain vmat2 inhibitors
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201808990QA (en) Compositions for topical application of compounds
SG11201811225RA (en) Ar+ breast cancer treatment methods
SG11201809605PA (en) Compositions for and method of treating acid-base disorders
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201810951RA (en) Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201804587QA (en) Isoindole compounds
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11202000263QA (en) Immunomodulatory retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201900405XA (en) Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201903076QA (en) Carbamoyl phenylalaninol compounds and uses therof
SG11201903312VA (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
SG11201803915UA (en) Echinomycin formulation, method of making and method of use thereof
SG11201900486WA (en) Treatment and prevention of sleep disorders
SG11201908603PA (en) Macrocyclic compound and uses thereof